Proton Therapy Treatment-Planning Software: Checking How Well RayStation and RayCare Work in Real Care
Official title: UW26028: Clinical Evaluation of a Treatment Planning Software and Oncology Information System for Proton Therapy
Run by University of Wisconsin, Madison · NCT07759999 · Data updated 2026-11-12
This study tests whether the RayStation 2025 and RayCare 2025 software upgrades reliably support delivering standard proton therapy to adults.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 180 (estimated) |
| Sponsor | University of Wisconsin, Madison Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Madison, Wisconsin) |
| Status | Recruiting |
| Started | July 15, 2026 |
| Main results expected | September 2027 |
| Study ends | September 2027 |
| Registry record updated | August 12, 2026 |
| Trial ID | NCT07759999 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) who are deemed clinically appropriate for standard-of-care proton therapy by their radiation oncologist and do not require anesthesia for therapy.
✕Probably not a fit
Patients not benefiting may include those not receiving proton therapy or those with contraindications to proton therapy or whose treatment plan is outside the standard-of-care approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will evaluate the clinical use and safety of updated treatment planning and workflow software (RayStation 2025 and RayCare 2025) in patients receiving standard-of-care proton therapy. The study focuses on how well the software integrates into routine treatment planning, scheduling, and delivery, with attention to safety and workflow performance. Eligible adults undergoing proton therapy will be enrolled at the University of Wisconsin Hospital and Clinics to assess practical use in real-world care. Treatment decisions remain guided by treating radiation oncologists, and all participants receive standard proton therapy.
Why it matters
Potential benefit: If successful, the software upgrades could streamline proton therapy planning and delivery, potentially improving efficiency and safety in patient care.
How similar studies have gone: Prior studies have shown that advanced planning and information systems can impact workflow positively, but this exact software combination for proton therapy is novel/less established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years at the time of consent. * Participant is deemed clinically appropriate for standard-of-care proton therapy by treating radiation oncologist and will not require anesthesia for therapy. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Participant has contraindications to proton therapy (per standard clinical guidelines). * Participant is unable to comply with routine treatment workflow or follow-up. * Participants who will be treated with a radiation plan of 5 fractions or fewer.
Where it's running
-
University of Wisconsin Hospital and Clinics (Carbone Cancer Center)
Madison, Wisconsin, United States Recruiting
Study contacts
- Principal investigator: Benjamin Durkee, MD, PhD — University of Wisconsin, Madison
- Study coordinator: Cancer Connect
- Email: clinicaltrials@cancer.wisc.edu
- Phone: 800-622-8922
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Protoacoustic Imaging to See Radiation Delivery in Proton Therapy
This study tests radioacoustic imaging with ultrasound to help doctors see where proton therapy is delivering radiation for liver and prostate cancer patients.
-
Proton total marrow irradiation before allogeneic transplant for high-risk AML or MDS
This trial tests whether adding proton-based total marrow irradiation to standard chemotherapy conditioning before allogeneic stem cell transplant can improve outcomes for adults with high-risk or relapsed/refractory AML or MDS.
-
Humanitas Proton Therapy (HU-PRO) Registry
This registry collects treatment and outcome data from adults with solid tumors who receive proton therapy to help understand safety and effectiveness.
-
Ultra‑ vs moderately hypofractionated proton therapy after lumpectomy for early breast cancer
This compares a very short (5-session) proton radiation schedule to a moderate (15-session) proton schedule for women 40 and older after lumpectomy for early-stage breast cancer.
-
Comparing two types of radiation therapy for breast cancer
This study is testing whether a new type of radiation therapy for breast cancer is safer and more effective than the standard treatment to help patients feel better and live longer.
-
Proton therapy for advanced cervical cancer
This study is testing whether combining proton therapy with standard chemotherapy and brachytherapy can help people with advanced cervical cancer while reducing side effects.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.